Grifols SA operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Grifols SA with three other
pharmaceutical manufacturers in Europe:
sales of 2.69 billion Euros [US$3.27 billion]
of which 85%
was Specialty Care),
(4.91 billion Euros [US$5.97 billion]
of which 35%
was Cimzia), and
Lonza Group AG
based in SWITZERLAND
(5.92 billion Swiss Francs [US$6.67 billion]
of which 70%
Grifols SA reported sales of 5.10 billion Euro (US$6.20 billion)
December of 2019.
increase of 13.6%
versus 2018, when the company's sales were 4.49 billion Euro.
Sales at Grifols SA have increased during each of the previous five years
(and since 2014, sales have increased a total of 52%).
Sales of Bio Supplies saw an increase
that was more than double the company's growth rate: sales were up
59.6% in 2019, from
167.00 million Euro to 266.54 million Euro.